Skip to main navigation Skip to search Skip to main content

Corrigendum to Interferon Alpha-2a as Treatment for Primary Acquired Melanosis With Atypia and for Primary Acquired Melanosis With Atypia Surrounding Conjunctival Melanoma. Am J Ophthalmol. 2026;285:318–323 (American Journal of Ophthalmology (2026) 285 (318–323), (S0002939426000425), (10.1016/j.ajo.2026.01.029))

  • Daniela Vaisman
  • , Jacob Pe'er
  • , Maya Eiger-Moscovich
  • , Michal Lotem
  • , Sharon Merims
  • , Shahar Frenkel*
  • *Corresponding author for this work

Research output: Contribution to journalComment/debate

Abstract

The authors regret that one of the article's author's names was misspelled as “Sharon Marims.” The correct spelling of the author's name is Sharon Merims. The authors would like to apologise for any inconvenience caused.

Original languageEnglish
JournalAmerican Journal of Ophthalmology
DOIs
StateAccepted/In press - 2026

Bibliographical note

Publisher Copyright:
© 2026 Elsevier Inc.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Corrigendum to Interferon Alpha-2a as Treatment for Primary Acquired Melanosis With Atypia and for Primary Acquired Melanosis With Atypia Surrounding Conjunctival Melanoma. Am J Ophthalmol. 2026;285:318–323 (American Journal of Ophthalmology (2026) 285 (318–323), (S0002939426000425), (10.1016/j.ajo.2026.01.029))'. Together they form a unique fingerprint.

Cite this